Header image

Transforming the Therapeutic Potential of ADCs with Next-Generation Cyanobacterial Toxin Payloads

  • Simris Biologics is advancing a pipeline of best-in-class ADC payloads, derived from proprietary cyanobacterial technologies.
  • Our unparalleled strain library is a rich source of novel payload candidates.
  • Our lead Microcystin variant has demonstrated industry-competitive efficacy and a promising safety profile.
  • We aim to create significant value through early-stage licensing deals with leading biopharma partners.

ANTIBODY DRUG CONJUGATES

Simris is building a powerful ADC payload platform designed to deliver enhanced efficacy, superior safety, and greater versatility.

CYANOBACTERIAL TOXIN STANDARDS AND REAGENTS

Our range of high-quality standards and reagents are trusted by water authorities around the world.

© 2025 Simris Biologics · Novel natural biologics sustainably sourced from cyanobacteria and microalgae. All rights reserved.

Simris Biologics is a part of the Simris Group.